Sensus Healthcare Sells Superficial Radiotherapy System to Cape Cod Hospital
28 September 2023 - 2:30PM
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical
device company specializing in highly effective, non-invasive,
minimally-invasive and cost-effective treatments for oncological
and non-oncological conditions, announces the shipment of an
SRT-100+™ System to Cape Cod Hospital in Hyannis, Massachusetts,
the second SRT-100+ System sold to a hospital in Massachusetts.
This sale represents the Company’s ongoing success in the U.S.
Northeast region as treating skin cancer with Sensus SRT technology
continues to draw interest from community hospital oncology
departments.
Jeffrey Martin, M.D., a radiation oncologist at
Cape Cod Hospital, said, “Non-melanoma skin cancers affect many
patients we serve. For those who may not be candidates for surgery,
or prefer a non-invasive alternative, radiation therapy is an
effective treatment option. This is particularly relevant for our
population on the Cape as many elderly residents who lived active
lives with significant sun exposure are at increased risk for skin
cancer. Superficial radiotherapy offers an advantage with its
ease of setup and positioning, while allowing for the treatment of
smaller fields than other forms of radiotherapy.”
Commenting on the sale, Joe Sardano, chairman
and chief executive officer of Sensus Healthcare, said, “More and
more hospitals around the country are inquiring about SRT as they
consider making non- invasive skin cancer treatments available in
their communities. It is becoming increasingly commonplace for
hospitals to treat a larger population suffering with cancer on an
outpatient basis, and our SRT systems offer an ideal non-surgical,
painless and cosmetically appealing option while also helping
hospitals to improve resource utilization.”
Sensus will be demonstrating its superficial
radiotherapy products at the American Society for Radiation
Oncology (ASTRO) Annual Meeting October 1-4 in San Diego. ASTRO
2023 participants are invited to visit Sensus Healthcare at Booth
2553 in the San Diego Convention Center to witness live product
demonstrations and interact with the company's knowledgeable
representatives. To schedule an appointment or for more information
about Sensus Healthcare's participation, please contact Sensus
Healthcare by visiting www.sensushealthcare.com.
About Sensus Healthcare
Sensus Healthcare, Inc. is a global pioneer in
the development and delivery of non-invasive treatments for skin
cancer and keloids. Leveraging its cutting-edge superficial
radiotherapy (SRT) technology, the company provides healthcare
providers with a highly effective, patient-centric treatment
platform. With a dedication to driving innovation in radiation
oncology, Sensus Healthcare offers solutions that are safe,
precise, and adaptable to a variety of clinical settings. For more
information, please visit www.sensushealthcare.com
Forward-Looking Statements
This press release includes statements that are,
or may be deemed, ''forward-looking statements.'' In some cases,
these statements can be identified by the use of forward-looking
terminology such as "believes," "estimates," "anticipates,"
"expects," "plans," "intends," "may," "could," "might," "will,"
"should," “approximately,” "potential" or negative or other
variations of those terms or comparable terminology, although not
all forward-looking statements contain these words.
Forward-looking statements involve risks and
uncertainties because they relate to events, developments, and
circumstances relating to Sensus, our industry, and/or general
economic or other conditions that may or may not occur in the
future or may occur on longer or shorter timelines or to a greater
or lesser degree than anticipated. Although we believe that we have
a reasonable basis for each forward-looking statement contained in
this press release, forward-looking statements are not guarantees
of future performance, and our actual results of operations,
financial condition and liquidity, and the development of the
industry in which we operate may differ materially from the forward
looking statements contained in this press release, as a result of
the following factors, among others: our ability to return to
profitability; our ability to sell the number of SRT units we
anticipate for the balance of 2023; the possibility that
inflationary pressures continue to impact our sales; our ability to
obtain and maintain the intellectual property needed to adequately
protect our products, and our ability to avoid infringing or
otherwise violating the intellectual property rights of third
parties; the level and availability of government and/or third
party payor reimbursement for clinical procedures using our
products, and the willingness of healthcare providers to purchase
our products if the level of reimbursement declines; the regulatory
requirements applicable to us and our competitors; our ability to
efficiently manage our manufacturing processes and costs; the risks
arising from doing business in China and other foreign countries;
legislation, regulation, or other governmental action that affects
our products, taxes, international trade regulation, or other
aspects of our business; concentration of our customers in the U.S.
and China, including the concentration of sales to one particular
customer in the U.S.; and other risks described from time to time
in our filings with the Securities and Exchange Commission,
including our Annual Report on Form 10-K and Quarterly Reports on
Form 10-Q.
To date, we do not expect that the Russian
invasion of Ukraine and global geopolitical uncertainty have not
had any particular impact on our business, but we continue to
monitor developments and will address them in future disclosures,
if applicable.
In addition, even if future events,
developments, and circumstances are consistent with the
forward-looking statements contained in this press release, they
may not be predictive of results or developments in future periods.
Any forward-looking statements that we make in this press release
speak only as of the date of such statement, and we undertake no
obligation to update such statements to reflect events or
circumstances after the date of this press release, except as may
be required by applicable law. You should read carefully our
"Introductory Note Regarding Forward-Looking Information" and the
factors described in the "Risk Factors" section of our periodic
reports filed with the Securities and Exchange Commission to better
understand the risks and uncertainties inherent in our
business.
Contact: LHA Investor
RelationsKim Sutton Golodetz212-838-3777kgolodetz@lhai.com
# # #
Sensus Healthcare (NASDAQ:SRTS)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Sensus Healthcare (NASDAQ:SRTS)
Historical Stock Chart
Von Mai 2023 bis Mai 2024